Selvita Announces Successful Completion of $41 M Book Building

*** NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN *** Krakow, Poland – 16 February 2018 – Selvita (WSE:SLV), one of the largest drug discovery companies in Europe, has received investment declarations implicating placement of all 2,200,000 shares offered in the H series public subscription. The issue…

More

Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer

Kraków, Poland – 06 February 2018 – Selvita S.A. (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer. Dr. Heeger will join Selvita…

More

Selvita presents at BIO-Europe 2017

Kraków, Poland – 06 November 2017 – Selvita is participating and presenting at the BIO-Europe 2017 conference, taking place on November 6-8, 2017, in Berlin, Germany. Selvita will be presenting in the Oncology category. The presentation will be held by Mr. Pawel Przewiezlikowski, Chief Executive Officer at Selvita, on November 8, at 10:15 am…

More

Selvita exhibits at the 35th Medicinal Chemistry Symposium in Japan

Kraków, Poland – 18  October 2017 – Selvita will participate in and exhibit during the upcoming 35th Medicinal Chemistry Symposium, which will take place in Nagoya, Japan, October 25 – 27, 2017. This symposium provides superb opportunities for participants to expand scientific knowledge and information on medicinal chemistry, and also to…

More

12345...10...